Literature DB >> 20650931

Antipsychotic dosing: how much but also how often?

Gary Remington1, Shitij Kapur.   

Abstract

Considerable focus has been devoted to how much antipsychotic is appropriate for optimal clinical response, although how often antipsychotics need to be administered is also less than clear. Clinicians are aware of the increased risk of relapse related to antipsychotic nonadherence/discontinuation, and current practice dictates continuous antipsychotic exposure with the goal of achieving steady state-levels to maintain effectiveness and prevent relapse. Does this mean we need to (or should) administer antipsychotics at least daily? There is a body of evidence challenging this long-established clinical axiom.

Mesh:

Substances:

Year:  2010        PMID: 20650931      PMCID: PMC2930338          DOI: 10.1093/schbul/sbq083

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  28 in total

1.  Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats.

Authors:  Peter Turrone; Gary Remington; Shitij Kapur; José N Nobrega
Journal:  Neuropsychopharmacology       Date:  2003-07-02       Impact factor: 7.853

Review 2.  Review of antipsychotic medication administration: a proposal of intermittent dosing.

Authors:  Roger A Boshes; Theo C Manschreck
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

3.  "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Gary Remington; Philip Seeman; Alan Feingold; Steve Mann; Chekkera Shammi; Shitij Kapur
Journal:  J Clin Psychiatry       Date:  2010-09-07       Impact factor: 4.384

Review 4.  Dopaminergic supersensitivity after neuroleptics: time-course and specificity.

Authors:  P Muller; P Seeman
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

5.  High-dose olanzapine for treatment-refractory schizophrenia.

Authors:  Vladimir Lerner
Journal:  Clin Neuropharmacol       Date:  2003 Mar-Apr       Impact factor: 1.592

6.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

Authors:  S Kapur; R Zipursky; C Jones; G Remington; S Houle
Journal:  Am J Psychiatry       Date:  2000-04       Impact factor: 18.112

7.  Intermittent pharmacotherapy in chronic schizophrenia.

Authors:  R F Prien; R D Gillis; E M Caffey
Journal:  Hosp Community Psychiatry       Date:  1973-05

8.  Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.

Authors:  G Chouinard; B D Jones
Journal:  Am J Psychiatry       Date:  1980-01       Impact factor: 18.112

Review 9.  Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.

Authors:  S Kapur; G Remington
Journal:  Biol Psychiatry       Date:  2001-12-01       Impact factor: 13.382

Review 10.  Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance.

Authors:  R M Post
Journal:  Life Sci       Date:  1980-04-21       Impact factor: 5.037

View more
  20 in total

1.  Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders.

Authors:  Mohammad-Reza Noori-Daloii; Majid Mojarrad; Ali Rashidi-Nezhad; Majid Kheirollahi; Ali Shahbazi; Mehdi Khaksari; Asghar Korzebor; Ali Goodarzi; Maryam Ebrahimi; Ali Reza Noori-Daloii
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

Review 2.  [Long-acting injectable antipsychotics. Overview and advice for daily routine care].

Authors:  S Köhler; A Heinz; P Sterzer
Journal:  Nervenarzt       Date:  2014-09       Impact factor: 1.214

Review 3.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

4.  Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval.

Authors:  Natashia Swalve; Ming Li
Journal:  Behav Pharmacol       Date:  2012-08       Impact factor: 2.293

Review 5.  Antipsychotic dosing: found in translation.

Authors:  Gary Remington; Gagan Fervaha; George Foussias; Ofer Agid; Peter Turrone
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

6.  Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function.

Authors:  Jun Gao; Rongyin Qin; Ming Li
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

7.  Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: further test of the motivational salience hypothesis.

Authors:  Min Feng; Nan Sui; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2012-09-28       Impact factor: 3.533

Review 8.  Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropharmacology       Date:  2019-05-08       Impact factor: 5.250

9.  Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.

Authors:  Monika Vinish; Ahmed Elnabawi; Jean A Milstein; Jesse S Burke; Jonathan K Kallevang; Kevin C Turek; Carien S Lansink; Istvan Merchenthaler; Aileen M Bailey; Bryan Kolb; Joseph F Cheer; Douglas O Frost
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-25       Impact factor: 5.176

10.  Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood.

Authors:  Jun Gao; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-06-03       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.